Hainan Shennong Seed Indus (300189.SZ) traded flat 0 % during a 24 hours period ending at 03:22 PM Central Europe on Monday 26th. One Hainan Shennong Seed Indus stock can currently be bought for about CNY 4.99 on popular exchanges. Current supply of Hainan Shennong Seed Indus stocks is 1 bn. Hainan Shennong Seed Indus has a current market capitalization of CNY 5.3 bn and approximately CNY 417.2 mn worth of Hainan Shennong Seed Indus was traded on exchanges in the last 24 hours. Since last month end, Hainan Shennong Seed Indus has traded -16.53 % down. Simple moving average of last 200 days is at CNY 5.35. The highest price of past 52 weeks was recorded at CNY 9.93 on 03/04/2026. 52 weeks low was at CNY 3.82 on 07/21/2026.
Here is how related stocks have performed in the past 24 hours:
Frontop (301313.SZ) traded flat 0 % and now trades at CNY 67.85. Current market capitalisation for Frontop is CNY 6.3 bn. Frontop, a listed company focused on physical AI, has attracted significant attention following a surge in its share price. The firm’s shares climbed more than 10 percent, reaching a new high that boosted its market value beyond 7 billion yuan. The rally coincides with a broader strengthening of the physical AI sector, where several peers such as Skyworth Digital and Tianyu Digital have also seen consecutive gains. Analysts note that Frontop’s performance reflects positive sentiment toward the sector’s recent breakthroughs, including advances in embodied reasoning datasets and the application of generative models to robotic control. Investors appear to be responding to the sector’s expanding potential, as reflected in the broader market’s allocation of capital toward physical AI-related stocks. The company’s upward trajectory continues to reinforce the perception that physical AI is gaining traction as a growth theme within the technology space.
Guizhou Bailing Phar (002424.SZ) traded flat 0 % and now trades at CNY 4.55. Guizhou Bailing Phar has a market capitalisation of CNY 6.3 bn. Guizhou Baili Group Pharmaceutical, formerly a prominent player in the indigenous medicine sector, reported a decline in revenue and profit for the first nine months of 2026. Management attributed the downturn to reduced market demand, lower sales volumes, and a new pricing structure that impacted revenue while allowing significant cost reductions. Despite the overall contraction, the company’s core product line—particularly a leading capsule formulation—remained the primary revenue driver. The firm also highlighted progress in its research pipeline, noting clinical milestones for a new therapeutic formulation that has received initial approval for trials. Recent regulatory actions have included sanctions on the company’s controlling individual for alleged financial misconduct, contributing to a sharp fall in the stock price and a loss of market value. The company faces ongoing challenges related to internal controls, governance, and market confidence as it seeks to restore its standing and comply with regulatory expectations.
Bank Of Jiujiang -H (6190.HK) traded up 0.19 % and now trades at HKD 2.6. Current market capitalisation for Bank Of Jiujiang -H is HKD 7.4 bn. Current price/earnings ratio for Bank Of Jiujiang -H is 13.19.
Xiamen Wanli Stone Stock C (002785.SZ) traded flat 0 % and now trades at CNY 28.17. Current market capitalisation for Xiamen Wanli Stone Stock C is CNY 6.3 bn. Xi’an Wanli Stone Stock Co., Ltd. reported its first‑quarter results for the year. Revenue for the quarter fell, while profit attributable to shareholders rose markedly. Over the full year to date, total revenue also declined, yet the company’s net profit increased significantly, driven in part by lower financial costs and higher investment income. Operating cash flow showed a strong positive swing, largely from higher cash received from sales and lower cash paid for goods. The company’s equity base grew modestly, and basic earnings per share reflected the profit improvement. Overall, the results suggest a resilient profitability profile amid a challenging revenue environment.
Beijing Sun-novo Pharmaceu (688621.SS) traded flat 0 % and now trades at CNY 54.58. Beijing Sun-novo Pharmaceu has a market capitalisation of CNY 6.3 bn. Current price/earnings ratio for Beijing Sun-novo Pharmaceu is 161.3. A recent release of third‑quarter holdings from several prominent Chinese funds highlights a mixed reaction to the broader market environment. Several managers have shifted focus from high‑growth technology stocks toward more stable sectors, such as utilities, energy, and healthcare. This realignment comes after a period of significant pullback in the technology and AI segments. At the same time, some funds have increased exposure to leading companies in the AI and semiconductor fields, reflecting a belief that these areas will recover in the medium term. The changes illustrate a strategic balance between defensive positioning and opportunistic investment in sectors that may rebound, while also maintaining a core emphasis on sectors with resilient cash flow and lower valuation compression.
About Hainan Shennong Seed Indus
Hainan Shennong Technology Co Ltd. is a Chinese company that specializes in breeding, producing, and selling hybrid rice seeds. Additionally, it offers technical services for hybrid rice seeds. Previously known as Grand Agriseeds Technology, Inc., the company changed its name to Hainan Shennong Gene Technology Co Ltd. in November 2015. Founded in 2000, its operations base is located in Haikou, China. The company went public at the Shenzhen Stock Exchange on March 16, 2011.